Supplementary materials

Formononetin attenuates atherosclerosis via regulating interaction between KLF4 and SRA in apoE^{-/-} mice

Running title: Formononetin retards atherosclerotic plaque development

Chuanrui Ma^{1,2,3}, Ronglin Xia⁷, Shu Yang ⁴, Lipei Liu⁵, Jing Zhang³, Ke Feng⁵, Yuna Shang⁵, Jingtian Qu^{1,2}, Lingwei Li^{1,2}, Ning Chen⁸, Shixin Xu^{1,2,3}, Wenwen Zhang⁹, Jingyuan Mao^{1,2}, Jihong Han^{5,6}, Yuanli Chen⁶, Xiaoxiao Yang⁶, Yajun Duan⁶, Guanwei Fan ^{1,2,3}

¹First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin, China; ²Tianjin Key Laboratory of Translational Research of TCM Prescription and Syndrome, Tianjin, China; ³State Key Laboratory of Modern Chinese Medicine, Tianjin University of Traditional Chinese Medicine, Tianjin, China; ⁴Department of Endocrinology, The Second Clinical Medical College of Jinan University, Shenzhen People's Hospital, Shenzhen, China; ⁵College of Life Sciences, Nankai University, Tianjin; China; ⁶School of Food and Biological Engineering, Hefei University of Technology, Hefei, China; ⁷Tianjin Hospital, Tianjin, China; ⁸School of Materials Science and Engineering, Tianjin University, Tianjin, China; ⁹Tianjin Central Hospital of Obstetrics and Gynecology, Tianjin, China

Correspondence should be addressed to:

Guanwei Fan, PhD

State Key Laboratory of Modern Chinese Medicine, Tianjin University of Traditional Chinese Medicine, Tianjin, China

No.88, Chang Ling Road, Li Qi Zhuang Jie, Xi Qing District, Tianjin, P.R. China; Tel: 86-22-27987796; Fax: 86-22-27987796; E-mail: guanwei.fan@tjutcm.edu.cn;



Figure S1. Formononetin does not affect expression of MMP9 /MMP2 and cell migration. (A) EAHY-926 cells were treated with formononetin overnight at the indicated concentrations. After treatment, total RNA was extracted, and expression of MMP9 and MMP2 were determined by q-QT-PCR, n=5. (B) After scratch, EAHY-926 cells were incubated in presence or absence of formononetin for 24 h, and migration rate was evaluated, n=5. Data are presented as mean \pm SEM, ns: not significantly different.



Figure S2. Formononetin decreases the cell apoptosis in lesion plaque and in vitro. (A) Apoptosis in lesion areas of the mice used in Figure 1A by TUNEL staining, n=5. (B) After treatment of ox-LDL (100 μ g mL-1) and formononetin (5 μ M), macrophages were incubated with FITC Annexin V in buffer containing propidium iodide (PI) and analyzed by flow cytometry. Cells undergoing apoptosis were FITC Annexin V positive and PI negative, n=5. Data are presented as mean \pm SEM, *P<0.05, significantly different as indicated.



Figure S3. Inhibition of SRA-mediated ox-LDL endocytosis by formononetin may be dynamin-mediated. (A) Peritoneal macrophages (PMs) were incubated with dynamin inhibitor dynasore (Dyn, 1 μ M) in presence or absence of formononetin (FNT, 5 μ M), simultaneously with DiI-oxLDL (10 μ g/mL), and then, ability of cellular uptake was assessed, n=5. Data are presented as mean ± SEM, *P<0.05, significantly different as indicated; ns, not significantly.



Figure S4. Formononetin reduces cellular ROS levels. Cellular ROS levels in RAW264.7 were determined by DCF staining, n=5. Data are presented as mean \pm SEM, *P<0.05, significantly different as indicated.



Figure S5. Effect of formononetin on the immune cell profile in lesion plaque. (A-E) Aortic root cross sections from mice used in Figure 1 were performed immunofluorescent staining with anti-Asialo GM1, CD4, CD22, 33D1, Mast Cell Chymase antibodies with quantitative analysis of MFI (mean fluorescent intensity), n=5. Data are presented as mean \pm SEM, *P<0.05 versus Ctrl group, ns: not significantly different.